Can early intervention in pediatric asthma improve long-term outcomes? A question that needs an answer

Pediatr Pulmonol. 2019 Mar;54(3):348-357. doi: 10.1002/ppul.24224. Epub 2019 Jan 4.

Abstract

Objective: Although many children with asthma do not experience persistence into adulthood, recent studies have suggested that poorly controlled asthma in childhood may be associated with significant airflow obstruction in adulthood. However, data regarding disease progression are lacking, and clinicians are not yet able to predict the course of a child's asthma. The goal of this article was to assess the current understanding of childhood asthma treatment and progression and to highlight gaps in information that remain.

Data sources: Nonsystematic PubMed literature search and authors' expertise.

Study selection: Articles were selected at the authors' discretion based on areas of interest in childhood asthma treatment and progression into adulthood.

Results: Uncontrolled asthma in early childhood can potentially have lasting effects on lung development, but it is unclear whether traditional interventions in very young children preserve lung function. Although not all children respond to standard interventions, certain asthma phenotypes have been identified that can help to understand which children may respond to a particular treatment.

Conclusion: Clinicians should monitor children's asthma control and pulmonary function over time to assess the long-term impact of an intervention and to minimize the effect of uncontrolled asthma, especially exacerbations, on lung development. New biologic therapies have shown promise in treating adults with severe, uncontrolled asthma, and some of these therapies are approved in the United States for children as young as age 6. However, knowledge gaps regarding the efficacy and safety of these treatments in younger children hamper our understanding of their effect on long-term outcomes.

Keywords: biologic; biomarkers; childhood; progression.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Biological Products / therapeutic use
  • Child
  • Child Development
  • Disease Progression
  • Humans
  • Lung / growth & development
  • Phenotype
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Anti-Asthmatic Agents
  • Biological Products